Properdin Antibody (Novelmed patent anti-Properdin) [DyLight 488]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28394G
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Functional
Label
DyLight 488 (Excitation = 493 nm, Emission = 518 nm)
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # Novelmed patent anti-Properdin
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Complement Factor P / Properdin
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications for Properdin Antibody (Novelmed patent anti-Properdin) [DyLight 488]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Properdin
Alternate Names
CFP, Complement Factor P, PFC
Gene Symbol
CFP
Additional Properdin Products
Product Documents for Properdin Antibody (Novelmed patent anti-Properdin) [DyLight 488]
Product Specific Notices for Properdin Antibody (Novelmed patent anti-Properdin) [DyLight 488]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...